drugset / Trial / NCT00276107
Study Evaluating Prevenar Vaccine in Healthy Infants
Non-randomizedSingle-groupOpen-labelPrevention
Summary
To determine the immunogenicity of Prevenar in infants immunized at 2, 4 and 6 months of age. To determine the antibody responses to the seven pneumococcal vaccine serotypes one month after second dose and determine the safety of Prevenar in infants immunized at 2,4 and 6 months of age.
Timeline
- Start
- 2004-12
- Primary completion
- —
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prevnar 13 | Vaccine | — | — |